Navigation Links
Lack of basic research putting patients at risk

Patients are suffering because not enough basic clinical research is being done, warns a senior doctor in this week's BMJ. He believes that medical academia is failing patients and clinicians by neglecting this vital area of research.

Basic observational research provides the information that doctors need to diagnose and treat patients appropriately, writes neurologist Professor Peter Rothwell. But in the field of neurology alone, many examples exist where a lack of basic data is the main barrier for effective treatment in routine practice.

For instance, little is known about the reliability of diagnosing stroke and, until very recently, no reliable data existed on the early risk of stroke in certain patients. Countless patients have suffered as a result, yet much of this research is easy and relatively cheap to do, so why has it not been done, he asks?

He calls into question whether medical academia, in its current form, is properly fit for purpose.

He believes that medical academia must improve its performance or, less preferably, be forced by politicians to prioritise appropriately. The recent emphasis on the development of clinical research is welcome, he says, but there are potential pitfalls.

Greatest of these is the tendency for clinical research to be defined too narrowly, with observational research necessary for effective clinical practice continuing to be neglected, he concludes.


'"/>

Source:BMJ-British Medical Journal


Page: 1

Related biology news :

1. New research questions basic tenet of neuron function
2. Scientists discover basic defect in cystic fibrosis airway glands
3. Columbia research lifts major hurdle to gene therapy for cancer
4. U of M researcher examines newly emerging deadly disease
5. NYU researchers simulate molecular biological clock
6. First atlas of key brain genes could speed research on cancer, neurological diseases
7. Vital step in cellular migration described by UCSD medical researchers
8. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
9. UCSD researchers maintain stem cells without contaminated animal feeder layers
10. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
11. New protein discovered by Hebrew University researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: